June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Validation of the Liverpool Uveal Melanoma Prognosticator Online for predicting survival of patients with choroidal melanoma
Author Affiliations & Notes
  • Sarah Willcox DeParis
    Ophthalmology, University of California San Francisco, San Francisco, CA
  • Bertil E Damato
    Ophthalmology, University of California San Francisco, San Francisco, CA
  • Footnotes
    Commercial Relationships Sarah DeParis, None; Bertil Damato, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5333. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sarah Willcox DeParis, Bertil E Damato; Validation of the Liverpool Uveal Melanoma Prognosticator Online for predicting survival of patients with choroidal melanoma. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5333.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Almost 50% of patients with choroidal melanoma develop metastatic disease despite successful eradication of the primary tumor. Accurate prognostication for patients with choroidal melanoma enhances care planning and improves patient quality of life, even when the prognosis is found to be poor. However, univariate prognostication based on anatomic, histologic or genetic predictors is not accurate enough to be relevant to individual patients. Further, the accuracy of various prognostic models is diminished by missing data.<br /> The Liverpool Uveal Melanoma Prognosticator Online (LUMPO) performs multivariate analysis of genetic, histologic and anatomical data, taking the patient’s age and sex into account and compensating for any missing data, providing prognostications that are accurate enough to be relevant to individual patients. This tool has been validated in the United Kingdom, but it remains to be seen whether it is generalizable to other patient populations. In this study, we seek to validate LUMPO in a group of patients who received care for choroidal melanoma at the University of California, San Francisco.

Methods: A retrospective chart review was performed for all patients who were treated for choroidal melanoma at the University of California, San Francisco between 2002 and 2007. Tumor characteristics were recorded including largest basal tumor diameter and thickness, extraocular extension, and ciliary body involvement. In patients who underwent enucleation, histopathological data was gathered, including the presence of epithelioid cells, vascular loops, and mitotic count. Survival data nonspecific to cause of death were gathered from the UCSF Cancer Center tumor database. The data were analyzed using the method previously outlined by Eleuteri et al.

Results: A total of 409 patients were compared to the established database of patients in the United Kingdom. Patient characteristics including age at diagnosis, race, gender, and laterality were found to be similar across both patient groups. Time from diagnosis to death was as well similar between the two groups. LUMPO accurately predicted survival in our cohort of patients, even when information was missing including histopathological and genetic data.

Conclusions: These results confirm that LUMPO is a valuable method of prognostication for choroidal melanoma and is generalizable to patients in the United States.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×